Decrease (-) Restore Default Increase (+)
In This Section Texas Health Research & Education Institute

Clinical Trials

Disease or Condition   Colon Cancer
Title   A prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint (Colon Cancer)
Description   To validate the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage II colon cancer.
IRB Number   Pro3743
Inclusion/Notes   INCLUSION:
  • Age = 18 years.

  • Adenocarcinoma of the colon (Note - patients with rectal cancer are not eligible).

  • Stage II or III, planned to be treated with radical surgery.

  • As stage is not determined at the time the tumor sample is taken, all samples from colon cancer patients (without signs of locally advanced disease or distant metastasis) can be sent in. Radical surgery typically refers to the removal of tumor and relevant ancillary lymph nodes.
  • Fresh tumor sample placed in RNA-retain with shipment at room temperature (not fixed in formalin).

  • Written informed consent.

  • Prior malignancy (with the exception of basal cell carcinoma or cervical dysplasia).

  • Any prior neo-adjuvant therapy.

  • Synchronous tumours.
Status   Completed
Location   Texas Health Presbyterian Hospital Dallas
Principal Name    Philip Joseph Huber MD
Contact Name   Lee Knox
Phone   (972) 739-3089

Online Tools


Helpful Info